The “Run Away” ending has everyone talking. Harlan Coben’s eight-episode thriller, inspired by his 2019 novel of the same name, is riding high on Netflix’s streaming charts, second only to “Stranger ...

Netflix’s latest Korean blockbuster The Great Flood has surged to the top of the platform’s global charts for nonglobal films, but audiences are divided over its cryptic ending and philosophical twist ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

SPOILER ALERT: This story contains spoilers for the first two episodes of “Pluribus,” streaming now on Apple TV. Not only did “Breaking Bad” earn four more seasons that cemented it as one of the ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...